Semintra

Active Ingredient:: Telmisartan
Brand:: Semintra
Origin:: European Union

Semintra (Telmisartan)

Telmisartan, the active ingredient in Semintra, is an angiotensin II receptor blocker presented as a tablet for oral use. It is indicated for the management of hypertension and for lowering cardiovascular risk in adult patients with established vascular disease or multiple risk factors.

GNH India supplies Semintra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medication for healthcare providers across global markets.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Semintra (telmisartan) acts on the renin‑angiotensin‑aldosterone system to control high blood pressure.
Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension.
Cardiovascular risk reduction: decreases the incidence of major cardiovascular events in high‑risk adults.
Stroke prevention: reduces the risk of stroke in patients with a history of cerebrovascular disease.

How It Works

Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from binding and activating the receptor. This inhibition leads to vasodilation, reduced aldosterone secretion, and decreased sodium and water retention, ultimately lowering systemic vascular resistance and blood pressure.

Side Effects

Common Side Effects

Dizziness or light‑headedness.
Headache.
Fatigue or tiredness.
Elevated blood potassium levels.
Mild gastrointestinal discomfort.
Increased serum creatinine.

Serious or Rare Side Effects

Angioedema involving face, lips, tongue or airway.
Severe hypotension causing fainting.
Acute kidney injury or worsening renal function.
Hepatic injury with jaundice.
Severe allergic reactions such as rash or eosinophilia.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

Monitor blood pressure regularly: ensure target levels are achieved without excessive drop.
Assess renal function: check serum creatinine and eGFR before and during treatment.
Check electrolytes: especially potassium, to avoid hyperkalaemia.
Use caution in severe hepatic impairment: dose adjustment may be required.
Avoid use during pregnancy: potential fetal toxicity.
Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Telmisartan may interact with several medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid)

Aliskiren in diabetic patients: increased risk of renal impairment and hyperkalaemia.
Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.
ACE inhibitors: combined use can lead to excessive potassium rise and renal dysfunction.
Lithium: telmisartan can raise lithium concentrations, risking toxicity.
NSAIDs: concurrent use may impair renal function.

Moderate Interactions (Monitor Closely)

Thiazide diuretics: may enhance antihypertensive effect, requiring dose adjustment.
Other antihypertensives: additive blood pressure lowering.
CYP2C9 inhibitors (e.g., fluconazole): may increase telmisartan plasma levels.
Antacids containing aluminium or magnesium: may reduce absorption if taken simultaneously.
Warfarin: monitor INR as telmisartan can affect anticoagulant control.

Frequently Asked Questions

Semintra contains telmisartan, an angiotensin II receptor blocker prescribed to treat hypertension and to lower cardiovascular risk in adults with established vascular disease or multiple risk factors.

Telmisartan selectively blocks the AT1 receptor for angiotensin II, preventing vasoconstriction and aldosterone release. This results in vessel relaxation, reduced sodium retention, and lowered blood pressure.

The dose of Semintra is individualized by the prescribing healthcare professional based on the patient’s condition, response, and clinical guidelines. Patients should follow the prescriber’s instructions.

Semintra is generally contraindicated in pregnancy because angiotensin II receptor blockers can cause fetal toxicity. Safety during breastfeeding has not been established, and a healthcare provider should be consulted.

To order Semintra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with ACE inhibitors, telmisartan (Semintra) offers similar blood‑pressure control but a lower incidence of cough. As an ARB, it is often chosen when patients cannot tolerate ACE inhibitors, and it provides additional benefits in cardiovascular risk reduction.

Semintra tablets should be stored at room temperature, below 25 °C, in the original packaging, protected from moisture and direct sunlight to maintain stability.

Semintra is taken orally, usually once daily, with or without food, as directed by the prescribing clinician.

Serious risks include angioedema, severe hypotension, acute kidney injury, hyperkalaemia, and rare cases of hepatic injury. Patients should seek immediate medical attention if they experience swelling of the face or throat, dizziness, or signs of kidney problems.

Semintra should not be used by patients with known hypersensitivity to telmisartan or any ARB, those with severe hepatic impairment, or pregnant women. Caution is also advised in patients with significant renal dysfunction or high potassium levels.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Semintra (Telmisartan)

Indications & Clinical Uses

How It Works